ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 6, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 6, 2012
News
Ranbaxy Issues Voluntary Recall of Atorvastatin Due to Quality Issues
By Patricia Van Arnum
The company issues voluntary recall of certain lots due to possible contamination with small glass particles.
EMA Publishes Plan to Deal with Supply Shortages
By Stephanie Sutton
The European Medicines Agency has published a plan to help Europe?s regulatory network prevent, mitigate and manage shortages of important medicines following manufacturing problems.
US Supreme Court to Hear Myriad Genetics' Gene Patentability Case
By Patricia Van Arnum
Myriad Genetics reports that the US Supreme Court has granted certiorari agreeing to hear the company's gene patentability case.
Lilly Releases Corporate Responsibility Update
By Amy Ritter
Eli Lilly released its annual report containing updates on progress and new initiatives in corporate responsibility.
Week of December 3, 2012: Biogen Idec Opens New RTP Facility; Tekmira, Marina Biotech Enter into License Agreement for UNA Technology; and More
Biogen Idec Opens New RTP Facility; Tekmira, Marina Biotech Enter into License Agreement for UNA Technology; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here